Urgent caution over new ‘Ozempic' side effect as scientists fear ‘tragic wave of people dying to lose weight'

BLOCKBUSTER 'Ozempic-style' fat jabs could increase the risk of depression and suicidal thoughts, experts have warned.
The injections' have allegedly helped celebrities including Sun columnist Jeremy Clarkson, Sharon Osbourne and ex-Prime Minister to shed some pounds.
Since then, the medicine's popularity has sky skyrocketed, with private prescriptions for jabs like such as Mounjaro set to hit one million this year.
But a new international study suggests the medicines could mess with mood-regulating hormone called dopamine.
"We urge the clinical prescribing community to proceed with caution to avoid another tragic wave of 'people dying to lose weight,'" study author, Dr Kenneth Blum, from Ariel University in California, US said.
More than 2,000 patients on the drugs have already joined a Facebook group seeking help for panic attacks and severe anxiety.
The page says: 'Our group is fast growing now, as more people start taking these meds and experiencing these scary side effects.'
The findings come as the European Medicines Agency launches a review into GLP-1 drugs after reports of serious psychiatric side effects, including suicidal thoughts.
GLP-1 is a naturally occurring hormone in the body that plays a crucial role in regulating blood sugar levels and appetite.
The drugs mimic the action of GLP-1 by making us feel full and helping people eat less.
They are used in the treatment of type 2 diabetes and obesity due to their dual benefits in blood sugar control and weight management.
For weight loss, GLP-1s target appetite regulation centres in the brain, increasing the sensation of fullness and reducing hunger.
There are many treatments available on the NHS to help with low mood and depression
They've also been shown to cut the risk of heart attacks and strokes.
But experts have warned about serious side effects too, including stomach paralysis, pancreas inflammation, and even vision loss.
In February, The Sun revealed that 82 Brits have died after using weight-loss and diabetes jabs such as Ozempic and Mounjaro. The details of why they died were not shared.
Earlier this year, an eight-year study of 160,000 obese patients found those on the drugs were nearly three times more likely to suffer depression and suicidal behaviour.
The paper, published in the journal Scientific Reports, found people on the drugs were twice as likely to have anxiety, compared to those not taking them.
The latest analysis, by scientists in the US, Brazil, Iran, and Israel, found long-term use of these drugs could disrupt signals sent by dopamine in the brain, potentially leading to depressive symptoms.
Dopamine, often called the 'feel-good' chemical, helps control pleasure and reward in the brain.
A review last year by the Medicines and Healthcare products Regulatory Agency (MHRA) did not find a link between the jabs and suicide risks.
In a new study, published in the journal Current Neuropharmacology, scientists looked at people with low dopamine activity - a condition linked to mood problems.
2
Using computer models, they found that GLP-1 drugs may affect how certain dopamine-related genes work, like DRD3, BDNF and CREB1.
This could upset dopamine levels in the brain and raise the risk of depression, anxiety, and suicidal thoughts.
The researchers are now urging clinicians not to over-prescribe the drugs, and consider genetic tests to better protect those who are already at a high risk of developing depression.
Professor Igor Elman of Harvard University, said: "While GLP1 receptor agonists hold promise for treating addictive and behavioral disorders, we must remain vigilant about their potential harm.
"This study is not intended to break the bubble of hope but to add a layer of precaution in their over-prescription."
Professor Panayotis K. Thanos of Buffalo University added: "Before prescribing GLP1 receptor agonists, it would be prudent to use genetic testing tools to assess a patient's dopamine function and addiction risk profile."
Wegovy and Mounjaro both warnings about possible mood changes, including depression on the medicine box.
Everything you need to know about fat jabs
Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases.
Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK.
Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market.
Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year.
How do they work?
The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight.
They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists.
They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high.
Can I get them?
NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics.
Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure.
GPs generally do not prescribe the drugs for weight loss.
Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk.
Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health.
Are there any risks?
Yes – side effects are common but most are relatively mild.
Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea.
Dr Sarah Jarvis, GP and clinical consultant at patient.info, said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.'
Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia.
Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health.
Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Independent

18 minutes ago

• The Independent

Mounjaro weight loss jab: All you need to know

GPs in England will be able to prescribe weight loss jabs for the first time on the NHS on Monday, as the health service begins its mass rollout. Some 220,000 people with the 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly, through the NHS over the next three years. Here the PA news agency takes a look at the drug and the rollout. – How does tirzepatide work? Tirzepatide, or Mounjaro, is an antidiabetic drug which lowers blood sugar levels and slows down how quickly food is digested. It makes you feel fuller for longer and therefore less hungry. If the jab is recommended by a healthcare professional, those using it will need to eat a balanced, reduced-calorie diet and to exercise regularly while taking it, according to the NHS website. – Who might be eligible for the drug? In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of more than 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. It was previously only accessible to patients through a special weight loss service, to severely obese people who also suffer from a range of other health problems. Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. – How would it be administered? The drug is usually delivered through a self-administered weekly injection which a doctor or nurse will show patients how to use, the NHS website says. – Who cannot take tirzepatide? Mounjaro is not recommended for those who are pregnant or planning to get pregnant, breastfeeding or have certain health conditions, according to the NHS. For those taking the contraceptive pill and using tirzepatide, the NHS recommends using an additional method of contraception, such as a condom, for the first four weeks of treatment and for four weeks after each dose increase as the contraceptive pill may not be absorbed by the body during this time. – What are the potential side effects? Potential side effects of tirzepatide include nausea, vomiting, diarrhoea and constipation, according to the National Institute for Health and Care Excellence.

Daily Mirror

an hour ago

• Daily Mirror

'King Kong' of weight loss jabs available on NHS to those in need from today

Around 220,000 people with "greatest need" are expected to receive Mounjaro, also known as tirzepatide and made by Lilly through the NHS over the next three years Hundreds of thousands of NHS patients will benefit from the 'King Kong' of weight loss jabs from today. Around 220,000 in "greatest need" are expected to receive Mounjaro in the mass roll out over the next three years. It is the brand name for the drug tirzepatide, orginally an antidiabetic treatment which lowers blood sugar and slows down how quickly food is digested. GPs in England are being allowed to prescribe Mounjaro to severely obese people for the first time. Patients needed to be on weight loss programmes to get the drug previously. It will initially be offered to people with a body mass index (BMI) score of over 40 in the first year of the roll out. ‌ They will also have conditions such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. Around 1.5m already take weight loss drugs in the UK, often through specialist weight loss services or via private prescription. ‌ Dr Claire Fuller, from NHS England, said: "This is an important next step in the rollout of weight loss drugs, with community-based services now able to offer this treatment from today. We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health and greater access to weight loss drugs will make a significant difference to the lives of those people. "These drugs are an important tool alongside the range of wraparound NHS support and advice on good nutrition and increasing physical activity. "They will be vital in helping some people lose weight and reduce their risk of serious long-term conditions." Anyone worried about their weight was urged to still speak with GPs and seek advice even if they were not eligible for the drug. Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: "We recognise the potential benefits of weight loss drugs. ‌ "But we know many GPs are concerned about the implications of the rollout of weight loss drugs into general practice, both in terms of workload and training to appropriately initiate and manage these treatments. "The college shares these concerns, which is why we were pleased NHS England suggested a phased roll-out of Mounjaro as a treatment for weight loss. "As and when this is escalated, appropriate resourcing for general practice, including access to 'wraparound' services, and training for GPs must follow." ‌ She added: "GPs and our teams are already working under intense workload and workforce pressures, and this must be factored into this rollout in order to guarantee it can be delivered safely. "More widely, whilst weight loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they mustn't be seen as a 'silver bullet' to aid weight loss. "We also need to focus on stopping people becoming overweight in the first place so they don't require medical intervention later." ‌ The rollout of the jabs should not "come at the expense of other weight loss services", she added. Olivier Picard, chairman of the National Pharmacy Association, told how demand for weight loss jabs continued to rise sharply. More GPs have been directing patients to local chemists to access these treatments privately. "We expect to see prescription volumes increase rapidly," he added. "However, NHS provision won't meet demand straight away, so we fully expect that many people will continue seeking it privately from a pharmacy. Pharmacists are experts in medication and many of us have lots of experience delivering weight loss injections as part of a package of care including lifestyle advice. "We are well placed to help roll out weight loss treatment on the NHS, with the right funding to support it. ‌ "The biggest concern we have is that prescribing these medications alone misses the point. They should be part of a comprehensive weight management strategy combining lifestyle coaching, exercise, and nutritional guidance. "In reality, many GPs lack the bandwidth to deliver the level of support needed to ensure proper understanding and follow-up. "As a result, we could end up in a situation where patients are prescribed the medication, lose weight, and then experience rebound weight gain once the course ends, simply because the foundational lifestyle changes weren't addressed." Around 29 percent of the adult population in the UK is obese. ‌ Health Secretary Wes Streeting warned that it is now one of the leading causes of ill health, costing the NHS billions. "Yet we now have the science, technology, and knowledge to end the obesity epidemic, if we seize this opportunity," he added. "Obesity jabs are used by 1.5 million people in the UK, mainly through private prescriptions. The NHS was founded on a promise to 'universalise the best'. We are determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay." Why it works: Mounjaro is being rolled out gradually to those in greatest need following its success on the open market. ‌ It contains the drug Tirzepatide which not only helps the obese to lose weight, but reduces risk of other health conditions. The fall in the number of stroke and heart attack victims should save the NHS billions in the long term. Mounjaro is administered through a weekly injection. It was originally developed as a treatment for people with Type 2 diabetes. Regulators authorised its use for weight loss in November 2023 in a bid to tackle obesity. Tirzepatide acts in the same way as hormones GIP and GLP-1. They are produced in the intestine after eating and make you feel full. They also slow the passage of food through the gut which means patients feel satisfied for longer. Mounjaro 'pens' are for the abdomen or thighs if injecting yourself or the back of the upper arms if someone else is giving you the jab. Experts stress that it is not a 'miracle' drug and ideally needs to be combined with a reduced-calorie diet and exercise. It could potentially be prescribed for 3.4m in England over time. Side effects include nausea, diarrhoea, vomiting, constipation and indigestion.

Leader Live

5 hours ago

• Leader Live

Mass rollout of weight loss jabs begins on NHS

Around 220,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly through the NHS over the next three years. The drug is an antidiabetic drug which lowers blood sugar levels and and slows down how quickly food is digested. From Monday, GPs in England will be allowed to prescribe Mounjaro to severely obese people who also suffer from a range of other health problems. Patients previously needed to access the drugs through a special weight loss service. But leading family doctors said some GPs have expressed concern about the additional workload linked to the rollout. And pharmacy experts also said there could be pressure on supplies of the drug. In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of over 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. Dr Claire Fuller, from NHS England, said: 'This is an important next step in the rollout of weight loss drugs, with community-based services now able to offer this treatment from today. 'We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health – and greater access to weight loss drugs will make a significant difference to the lives of those people. 'These drugs are an important tool alongside the range of wraparound NHS support and advice on good nutrition and increasing physical activity, which will be vital in helping some people lose weight and reduce their risk of serious long-term conditions. 'While not everyone will be eligible for weight loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'While we recognise the potential benefits of weight loss drugs, we know many GPs are concerned about the implications of the rollout of weight loss drugs into general practice, both in terms of workload and training to appropriately initiate and manage these treatments. 'The college shares these concerns, which is why we were pleased NHS England suggested a phased roll-out of Mounjaro as a treatment for weight loss. As and when this is escalated, appropriate resourcing for general practice – including access to 'wraparound' services – and training for GPs must follow. GLP-1s like #Ozempic, #Saxenda, #Wegovy, or #Mounjaro are not an easy #weightloss hack. Find out more about:🔵what they are ❓🔵how they're used 💊🔵who they help 💪 🔗Learn more: — EU Medicines Agency (@EMA_News) January 4, 2025 She added: 'GPs and our teams are already working under intense workload and workforce pressures, and this must be factored into this rollout in order to guarantee it can be delivered safely. 'More widely, whilst weight loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they mustn't be seen as a 'silver bullet' to aid weight loss. 'We also need to see a focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later.' Dr Hawthorne said there is no 'one size fits all approach' and that the rollout of the jabs should not 'come at the expense of other weight loss service'. She continued: 'The roll-out of weight loss medications in the NHS will need to be consistently evaluated to ensure that there is evidence that these prescriptions are of long-term benefit to patients.' Olivier Picard, chairman of the National Pharmacy Association, said: 'The demand for weight loss jabs continues to rise sharply, and more GPs have been directing patients back to pharmacies after initial inquiries, to access these treatments privately. 'As the NHS is now moving to implement National Institute for Health and Care Excellence (Nice) guidance, and tirzepatide becomes prescribable to more patients, we expect to see prescription volumes increase rapidly. 'However, NHS provision won't meet demand straight away, so we fully expect that many people will continue seeking it privately from a pharmacy. 'Pharmacists are experts in medication and many of us have lots of experience delivering weight loss injections as part of a package of care including lifestyle advice. 'We are well placed to help roll out weight loss treatment on the NHS, with the right funding to support it. 'The biggest concern we have is that prescribing these medications alone misses the point. 'They should be part of a comprehensive weight management strategy – combining lifestyle coaching, exercise, and nutritional guidance. In reality, many GPs lack the bandwidth to deliver the level of support needed to ensure proper understanding and follow-up. 'As a result, we could end up in a situation where patients are prescribed the medication, lose weight, and then experience rebound weight gain once the course ends – simply because the foundational lifestyle changes weren't addressed.' Around 29% of the adult population in the UK is obese. Health Secretary Wes Streeting said: 'Obesity is now one of the leading causes of ill health, costing the NHS billions. Yet we now have the science, technology, and knowledge to end the obesity epidemic, if we seize this opportunity. 'Obesity jabs are used by 1.5 million people in the UK, mainly through private prescriptions. The NHS was founded on a promise to 'universalise the best', and this Government is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay. 'This rollout is an important step in making these medicines more widely available, and beginning to shift the focus of healthcare from sickness to prevention, which our forthcoming 10-year plan will deliver.'